Notably, the work by Mengyao Xie and colleagues has provided compelling evidence that Gracillin can effectively inhibit TGF-β1-driven p-STAT3 activation both in vitro and in vivo, resulting in significant attenuation of PF progression (Xie et al., 2023). The gene discussed is STAT3; the disease is pemphigus foliaceus.